JAJoshua J. Augustine

Joshua J. Augustine

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Joshua J. Augustine has a total of 66 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A Pre-Kidney Transplant Blood-Based Next-Generation Sequencing Assay to Predict Early Acute Rejection

    by Beatrice P. Concepcion, Oriol Bestard, Milagros Samaniego-Picota, Rohini Prashar, M. Javeed Ansari, Giorgia Comai, Elisa Gessaroli, Lionel Rostaing, Federico Alberici, Roslyn B. Mannon, et al.

    Key Points: Pretransplant early acute rejection risk stratification offers a novel approach to personalized immunosuppression management in patients who received a kidney transplant. Stratifying immunologic risk independent of donor characteristics may help guide immunosuppression management in patients who received a kidney transplant. The pretransplant risk assessment gene set reflects metabolic and immune pathways involved in T-cell– and antibody-mediated mechanisms of transplant rejection. Background: Although donor and recipient characteristics are used to estimate graft failure risk, they remain limited in predicting early acute rejection (EAR). We developed and validated a next-generation sequencing assay targeting the pretransplant immunologic profile to predict EAR following kidney transplantation. Methods: This prospective, international study enrolled 321 kidney transplant participants across 13 sites, forming discovery and validation cohorts. Peripheral blood was collected before transplant and at 1, 3, 6, 12, and 24 months post-transplant, with protocol biopsies performed at 3 and 12 months, as well as any indication biopsies. Biopsies were assessed by a blinded central pathologist according to the 2019 Banff criteria. The pretransplant risk assessment (PTRA) test to evaluate RNA expression of a 29-gene signature algorithm designed to predict EAR risk was clinically validated using 122 deceased donor kidney transplant recipients. Results: PTRA classified 31 of 122 participants (25%) as high risk and 91 (75%) as low risk. There were nine EAR events in the first 60 days post-transplant: 6/31 (19%) in the high-risk group and 3/91 (3%) in the low-risk group. PTRA discrimination for EAR at 60 days post-transplant yielded an area under the curve of 0.78 (95% confidence interval [CI], 64.4 to 91.5), P < 0.001. A cutoff of ≤45 was defined as low risk and >45 as high risk for EAR within 60 days post-transplant. Sensitivity was 0.67 (95% CI, 0.36 to 0.97), specificity 0.78 (95% CI, 0.70 to 0.86), positive predictive value 0.19 (95% CI, 0.05 to 0.33), and negative predictive value 0.97 (95% CI, 0.93 to 1.00). The odds ratio comparing patients identified as high versus low risk by PTRA was 7.04 (95% CI, 1.64 to 30.2), P = 0.009. Conclusions: This study validates the ability of PTRA to stratify kidney transplant recipients as high or low risk for EAR using a pretransplant transcriptomic profile, with implications for graft health and personalized treatment management.


  • Outcomes of Deceased Donor Kidney Transplants Allocated Out of Sequence in the United States

    by Anne M. Huml, Joshua J. Augustine, Emilio D. Poggio, Alvin Wee, Susana Arrigain, Rocio Lopez, Jesse D. Schold

    Key Points: We used national data to examine the outcomes of kidney transplant allocated as out of sequence offers to transplant centers in the United States. Short-term kidney graft failure does not differ between kidneys that were allocated as out of sequence offers versus standard allocation. Background: Changes in kidney allocation policies and regulations of Organ Procurement Organizations have affected the volume of organ offers and challenged transplant providers. One consequence is increased kidneys allocated out of sequence (OOS). Methods: Retrospective observational study using Scientific Registry of Transplant Recipient data from 2021 to 2023, we analyzed donor and recipient characteristics for OOS versus standard kidney allocation and multivariable Cox models to evaluate graft survival. We also compared paired donors (one kidney OOS and the other standard allocation). Results: Annual OOS kidney allocation rates increased from 5.4% in 2021 to 18.4% in 2023. High OOS-use centers increased from 5 (2.2%) between 2021 and June 2022 to 37 (17%) in 2023. Listing at a high-OOS usage center was associated with increased rate of deceased donor transplantation (adjusted hazard ratio [AHR], 3.07; 95% confidence interval [CI], 2.90 to 3.25). Recipients of OOS allocation were more likely to be male (66% versus 59%), White race (38% versus 32%), privately insured (29% versus 24%), and preemptively transplanted (18% versus 10%). Overall graft loss was not significantly different between OOS and standard allocated transplants (AHR, 0.94; 95% CI, 0.85 to 1.05), consistent in paired donor analysis (AHR, 1.10; 95% CI, 0.86 to 1.41). Conclusions: Short-term kidney graft failure does not differ between OOS and standard allocation. High-OOS kidney centers have higher deceased donor transplant rates. Further investigation is needed to understand demographic differences and factors explaining OOS allocation.


  • Open Access

    Prospective observational study to validate a next-generation sequencing blood RNA signature to predict early kidney transplant rejection

    by Oriol Bestard, Joshua Augustine, Alvin Wee, Emilio Poggio, Roslyn B. Mannon, Mohammed Javeed Ansari, Chandra Bhati, Daniel Maluf, Scott Benken, Nicolae Leca, et al.


  • Open Access

    Performance of estimated glomerular filtration rate equations in Black living kidney donor candidates

    by Joshua J. Augustine, Aimen Liaqat, Susana Arrigain, Jesse D. Schold, Emilio D. Poggio

    Introduction: New estimated glomerular filtration rate (eGFR) equations using serum creatinine and/or cystatin C have been derived to eliminate adjustment by perceived Black ancestry. We sought to analyze the performance of newer eGFR equations among Black living kidney donor candidates.Methods: Black candidates (n = 64) who had measured iothalamate GFR between January 2015 and October 2021 were included, and eGFR was calculated using race adjusted (eGFRcr2009 and eGFRcr‐cys2012) and race unadjusted (eGFRcys2012, eGFRcr2021, and eGFRcr‐cys2021) CKD‐EPI equations. Bias and accuracy were calculated.Results: The eGFRcr2021 equation had a negative bias of 9 mL/min/1.73 m2, while other equations showed a modest positive bias. Accuracy within 10% and 30% was greatest using the eGFRcr‐cys2021 equation. With the eGFRcr2021 equation, 9.4% of donors with an mGFR > 80 mL/min/1.73 m2 were misclassified as having an eGFR < 80 mL/min/1.73 m2. eGFR was also compared among 18 kidney donors at 6–24 months post‐donation. Post‐donation, the percentage of donors with an eGFR < 60 mL/min/1.73 m2 was 44% using the eGFRcr2021 equation compared to 11% using the eGFRcr‐cys2021 equation.Conclusion: The CKD‐EPICr2021 equation appears to underestimate true GFR in Black living donor candidates. Alternatively, compared to CKD‐EPICr2021, the CKD‐EPICr‐CysC2021 equation appears to perform with less bias and improved accuracy.


  • Emphysematous pyelonephritis in a kidney transplant recipient

    by Mohamed Hassanein, Omar Aleter, Brian R. Stephany, Mohamed Eltemamy, Joshua J. Augustine


  • Continuous function of 80 primary renal allografts for 30–47 years with maintenance prednisone and azathioprine/mycophenolate mofetil therapy: A clinical mosaic of long‐term successes

    by William E. Braun, Leal Herlitz, Jianbo Li, Jesse Schold, Emilio Poggio, Brian Stephany, Richard Fatica, Joseph Nally, Kathleen Brown, Robert Fairchild, et al.

    Eighty primary renal allograft recipients, 61 living‐related and 19 deceased donor, transplanted from 1963 through 1984 had continuous graft function for 30–47 years. They were treated with three different early immunosuppression programs (1963–1970: thymectomy, splenectomy, high oral prednisone; 1971–1979: divided‐dose intravenous methylprednisolone; and 1980–1984: antilymphocyte globulin) each with maintenance prednisone and azathioprine, and no calcineurin inhibitor. Long‐term treatment often included the anti‐platelet medication, dipyridamole. Although both recipient and donor ages were young (27.2 ± 9.5 and 33.1 ± 12.0 years, respectively), six recipients with a parent donor had >40‐year success. At 35 years, death‐censored graft survival was 85.3% and death with a functioning graft 84.2%; overall graft survival was 69.5% (Kaplan–Meier estimate). Biopsy‐documented early acute cellular and highly probable antibody‐mediated rejections were reversed with divided‐dose intravenous methylprednisolone. Complications are detailed in an integrated timeline. Hypogammaglobulinemia identified after 20 years doubled the infection rate. An association between a monoclonal gammopathy of undetermined significance and non‐plasma‐cell malignancies was identified. Twenty‐seven azathioprine‐treated patients tested after 37 years had extremely low levels of T1/T2 B lymphocytes representing a “low immunosuppression state of allograft acceptance (LISAA)”. The lifetime achievements of these patients following a single renal allograft and low‐dose maintenance immunosuppression are remarkable. Their success evolved as a clinical mosaic.


  • Diagnostic Performance of Blood Pressure Measurement Modalities in Living Kidney Donor Candidates

    by Sherif Armanyous, Yasushi Ohashi, Michael Lioudis, Jesse D. Schold, George Thomas, Emilio D. Poggio, Joshua J. Augustine

    Background and objectives: Precise BP measurement to exclude hypertension is critical in evaluating potential living kidney donors. Ambulatory BP monitoring is considered the gold standard method for diagnosing hypertension, but it is cumbersome to perform. We sought to determine whether lower BP cutoffs using office and automated BP would reduce the rate of missed hypertension in potential living donors. Design, setting, participants, & measurements: We measured BP in 578 prospective donors using three modalities: (1) single office BP, (2) office automated BP (average of five consecutive automated readings separated by 1 minute), and (3) ambulatory BP. Daytime ambulatory BP was considered the gold standard for diagnosing hypertension. We assessed both the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) and the American College of Cardiology/American Heart Association (ACC/AHA) definitions of hypertension in the cohort. Empirical thresholds of office BP and automated BP for the detection of ambulatory BP–diagnosed hypertension were derived using Youden index, which maximizes the sum of sensitivity and specificity and gives equal weight to false positive and false negative values. Results: Hypertension was diagnosed in 90 (16%) prospective donors by JNC-7 criteria and 198 (34%) prospective donors by ACC/AHA criteria. Masked hypertension was found in 3% of the total cohort by JNC-7 using the combination of office or automated BP, and it was seen in 24% by ACC/AHA guidelines. Using Youden index, cutoffs were derived for both office and automated BP using JNC-7 (<123/82 and <120/78 mm Hg) and ACC/AHA (<119/79 and <116/76 mm Hg) definitions. Using these lower cutoffs, the sensitivity for detecting hypertension improved from 79% to 87% for JNC-7 and from 32% to 87% by ACC/AHA definition, with negative predictive values of 95% and 87%, respectively. Missed (masked) hypertension was reduced to 2% and 4% of the entire cohort by JNC-7and ACC/AHA, respectively. Conclusions: The prevalence of hypertension was higher in living donor candidates using ACC/AHA compared JNC-7 definitions. Lower BP cutoffs in the clinic improved sensitivity and led to a low overall prevalence of missed hypertension in prospective living kidney donors.


  • Significantly Lower Rates of Kidney Transplantation among Candidates Listed with the Veterans Administration: A National and Local Comparison

    by Joshua J. Augustine, Susana Arrigain, Krishna Balabhadrapatruni, Niraj Desai, Jesse D. Schold

    Background The process for evaluating kidney transplant candidates and applicable centers is distinct for patients with Veterans Administration (VA) coverage. We compared transplant rates between candidates on the kidney waiting list with VA coverage and those with other primary insurance. Methods Using the Scientific Registry of Transplant Recipients database, we obtained data for all adult patients in the United States listed for a primary solitary kidney transplant between January 2004 and August 2016. Of 302,457 patients analyzed, 3663 had VA primary insurance coverage. Results VA patients had a much greater median distance to their transplant center than those with other insurance had (282 versus 22 miles). In an adjusted Cox model, compared with private pay and Medicare patients, VA patients had a hazard ratio (95% confidence interval) for time to transplant of 0.72 (0.68 to 0.76) and 0.85 (0.81 to 0.90), respectively, and lower rates for living and deceased donor transplants. In a model comparing VA transplant rates with rates from four local non-VA competing centers in the same donor service areas, lower transplant rates for VA patients than for privately insured patients persisted (hazard ratio, 0.72; 95% confidence interval, 0.65 to 0.79) despite similar adjusted mortality rates. Transplant rates for VA patients were similar to those of Medicare patients locally, although Medicare patients were more likely to die or be delisted after waitlist placement. Conclusions After successful listing, VA kidney transplant candidates appear to have persistent barriers to transplant. Further contemporary analyses are needed to account for variables that contribute to such differential transplant rates.


  • The Impact of Direct Antiviral Therapy for Hepatitis C (DAA) on Acute Rejection and Donor Specific Antibody Formation in Kidney Transplant Recipients, Evidence from Surveillance Biopsies

    by Ziad Zaky, Leal Herlitz, Joshua Augustine

    Hepatitis C virus infection (HCV) has historically portended a poor outcome after kidney transplantation. With the recent advent of direct antiviral agents (DAA), there has been a high rate of successful HCV eradication after transplantation. However, data on immunologic injury to the allograft after therapy are lacking. We studied 20 HCV+ kidney transplant patients (KT) who underwent DAA treatment with median follow up of 26 mos (range 11-117). We collected data on demographics, DAA regimen, CNI levels, allograft function, donor specific antibodies (DSA), and surveillance &/or for cause allograft biopsies findings. Mean age±SD was 61.9±6.1yo, (18M/2F), 75% were non-Caucasian, all were infected with genotype 1, the DAA regimen was ledipasvir/sofosbuvir (n=19), sofosbuvir and simeprevir (n=1), and 95% achieved sustained virological response. There was no statistical difference between the mean serum creatinine (Cr) and proteinuria (P/Cr ratio) pre DAA treatment and at the last follow up (Cr 1.39 &1.42 mg/dl, p=0.58, P/Cr 0.74-0.91, p=0.64). 11 KT had biopsy proven rejection (pre DAA n=6, post DAA n=5). Mean follow up time from DAA start to last follow up was 21.7 mo±10.1. Of notice all Antibody mediated rejections (AMR) were in the post DAA (table). There was a downtrend in mean Tacrolimus levels (n=18) during DAA with statistical significant difference 2 weeks prior to DAA start and week 12 of DAA treatment (-3.22, p=0.0042) (Figure). There is a significant decline in mean CNI levels during DAA therapy in KT.In addition, despite relatively stable allograft function in terms of serum creatinine and proteinuria, there is a significant incidence of clinical and subclinical rejection 5/20 (25%) especially AMR 4/5 (80%) detected by protocol and for-cause biopsies.This study highlights the need for close monitoring of immunosuppression, as well as immunologic and histologic surveillance during DAA administration for HCV.